ArticleNeurology and therapy2026
Neutrophil to Lymphocyte Ratio and Neurological Outcome in Ischemic Stroke at 4.5 to 24 Hours: A Post Hoc Analysis of TRACE-III Trial.
Article in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05141305 (A Phase 3, Multicenter, Prospective, Randomized, Open-label, Blinded-endpoint), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 3, Multicenter, Prospective, Randomized, Open-label, Blinded-endpoint (PROBE) Controlled Trial of Tenecteplase Versus Standard Medical Treatment for Acute Ischemic Stroke Due to Anterior Circulation Large Vessel Occlusion With Perfusion Mismatch up to 24 Hours of Symptom Onset
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
introductionWhether neutrophil to lymphocyte ratio (NLR), as a marker of increased inflammatory response, modifies the efficacy and safety of tenecteplase is uncertain in patients 4.5-24 h after stroke onset. We investigated this in the Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-III (TRACE-III) trial.
methodsTRACE-III was a phase 3, multicenter, prospective, open-label, randomized, blinded-endpoint trial that enrolled 516 patients from 58 centers in China between January 2022 and November 2023. Patients had anterior large vessel occlusion and evidence of salvageable brain tissue on perfusion imaging, presented 4.5-24 h after symptom onset, and were randomized 1:1 to intravenous tenecteplase (intervention) or standard medical treatment (control). The primary efficacy and safety outcomes were modified Rankin scale score of 0-1 at 90 days and symptomatic intracranial hemorrhage or death, respectively. This post hoc analysis in 513 patients with complete admission NLR data compared outcomes in patients with elevated NLR (> first quartile) and non-elevated NLR (≤ first quartile).
resultsIn the elevated NLR group (> 3.0), tenecteplase was associated with increased functional independence (61 [30.2%] vs. 36 [19.6%]; adjusted relative rate [aRR] 1.51; 95% confidence interval [CI] 1.05-2.17; P = 0.03) compared to standard medical treatment. This benefit was not observed in the non-elevated NLR group (26 [41.9%] vs. 25 [38.5%]; aRR 1.12; 95% CI 0.73-1.73). Safety outcomes did not differ in either the elevated or non-elevated NLR groups.
conclusionBaseline NLR may provide a potential signal for differential treatment response to intravenous tenecteplase in patients with acute ischemic stroke, although these exploratory findings require further validation in independent studies.
trial registrationTRACE-III is registered with ClinicalTrials.gov, NCT05141305.
Indexed as
Identifiers
42886317What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.